Get started
PFIZER LTDPFIZER LTDPFIZER LTD

PFIZER LTD

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

PFIZER trade ideas

Pfizer Ltd. - Short Position AnalysisChart Overview: The chart indicates that the stock is in a clear downtrend, following a descending channel pattern. The price is nearing a key horizontal support level (marked in black), and a breakdown below this level may present a shorting opportunity. Trade Setup for Short Position: 1.Entry Trigger: Below ₹5,028 on a daily closing basis. 2.Targets: Target 1: ₹4,885 (first demand zone). Target 2: ₹4,760 (strong support and lower boundary of the descending channel). 3.Stop Loss: Above ₹5,187 (recent swing high and red-dotted resistance level). 4.Risk-Reward Ratio: Ensure a favorable ratio of at least 1:2. Alternate Scenario: If ₹5,028 holds as support, the stock might see a pullback toward ₹5,187, where selling pressure could resume.
NSE:PFIZERShort
by AngshumanSaikia
PFIZER LTD S/R Support and Resistance Levels: Support Levels: These are price points (green line/shade) where a downward trend may be halted due to a concentration of buying interest. Imagine them as a safety net where buyers step in, preventing further decline. Resistance Levels: Conversely, resistance levels (red line/shade) are where upward trends might stall due to increased selling interest. They act like a ceiling where sellers come in to push prices down. Breakouts: Bullish Breakout: When the price moves above resistance, it often indicates strong buying interest and the potential for a continued uptrend. Traders may view this as a signal to buy or hold. Bearish Breakout: When the price falls below support, it can signal strong selling interest and the potential for a continued downtrend. Traders might see this as a cue to sell or avoid buying. 20 EMA (Exponential Moving Average): Above 20 EMA(50 EMA): If the stock price is above the 20 EMA, it suggests a potential uptrend or bullish momentum. Below 20 EMA: If the stock price is below the 20 EMA, it indicates a potential downtrend or bearish momentum. Trendline: A trendline is a straight line drawn on a chart to represent the general direction of a data point set. Uptrend Line: Drawn by connecting the lows in an upward trend. Indicates that the price is moving higher over time. Acts as a support level, where prices tend to bounce upward. Downtrend Line: Drawn by connecting the highs in a downward trend. Indicates that the price is moving lower over time. It acts as a resistance level, where prices tend to drop. RSI: RSI readings greater than the 70 level are overbought territory, and RSI readings lower than the 30 level are considered oversold territory. Combining RSI with Support and Resistance: Support Level: This is a price level where a stock tends to find buying interest, preventing it from falling further. If RSI is showing an oversold condition (below 30) and the price is near or at a strong support level, it could be a good buy signal. Resistance Level: This is a price level where a stock tends to find selling interest, preventing it from rising further. If RSI is showing an overbought condition (above 70) and the price is near or at a strong resistance level, it could be a signal to sell or short the asset. Disclaimer: I am not a SEBI registered. The information provided here is for learning purposes only and should not be interpreted as financial advice. Consider the broader market context and consult with a qualified financial advisor before making investment decisions.
NSE:PFIZER
by zenthosh
PFIZER | 2x returns | Breakout of 3 year resistance| PFIZER | Monthly time frame Stock has been moving along the upward blue dotted parallel channel since listing in 1994 Stock has bounced from a recent “higher low” made in Mar 2023 Stock riding above 20-, 50- & 200-month moving averages RSI > 70, indicating solid bullish momentum MACD crossover extended and is above the 0 line, indicating bullish momentum Weekly time frame Stock has been following the rounded bottom formation for last 3 years Stock is trading near the white resistance trend line Double Breakout on the cards, from the rounded bottom formation + trend line Stock riding above 20-, 50- & 200-week moving averages Golden crossover just now completed RSI = 80, indicating aggressive bullish momentum MACD extending the crossover & above the 0 line, indicating bullish momentum Daily time frame Stock riding along the dotted white parallel channel since Jul 2024 Breakout possible if the stock crosses the white resistance trend line of 6100 Stock riding above 20-, 50- & 200-day moving averages RSI > 65, indicating bullish momentum MACD is well above the 0 line, indicating solid momentum Conclusion Entry: 6,200 Stop Loss: 5,000 Target 1: 7,867 Target 2: 10,614 Target 3: 13,361 Fundamentals ROCE = 22% {Ideal > 15} ROE = 16.1% {Ideal > 15} Stock PE (45) < Industry PE (48) {Stock not overvalued} Int Coverage = 57 {Ideal > 2} Debt to equity = 0.01 {Ideal value < 1} Promoter stake has remained consistent over the years > 63% FII and DII participation increased in previous 2 quarters
NSE:PFIZERLong
by shyamsrk2
Pfizer (PFE) – Post-Covid Growth Prospects Post-Covid Growth Prospects Supporting Arguments • Pipeline and portfolio advancement ensures better long-term growth prospects for Pfizer’s pharmaceutical business • Favorable fundamental and technical analysis Investment Thesis Pfizer is an American multinational pharmaceutical and biotechnology corporation, specializing in the development of medicines and vaccines across a wide range of disciplines including oncology, immunology, rare diseases and other clinical areas. The Company’s stock experienced a lengthy period of falling prices after the peak earnings driven by the pandemic. In our opinion, the downturn has concluded with Pfizer now enhancing its pipeline and product lineup to secure long-term business growth. The Company’s performance in the first half of 2024 was encouraging, as Pfizer's pipeline improvements began to translate into revenue growth within its core product portfolio. In Q2 2024, Pfizer's total revenue grew by 2.1% compared to the previous year, although the core portfolio’s growth is overshadowed by reduced earnings from COVID-19 treatments, including Paxlovid and Comirnaty. Excluding the impact of COVID products, the Company achieved a 13.4% y/y increase in revenue, with 7.5% of this growth coming from proceeds associated with Seagen, which was acquired late last year. In our view, the updated product portfolio significantly strengthens Pfizer’s long-term revenue growth trajectory. The Company has wisely administered the funds earned during the COVID-19 pandemic, significantly revamping its product portfolio through both M&As and in-house R&D. The Q2 2024 report evoked target and recommendation revisions by analysts. We also expect Pfizer’s progress to facilitate further enhancement of investors’ perception of the Company as a growing business. The first half of 2024 saw Pfizer achieving key milestones in the strategic directions announced at the start of the year. Key strategic priorities are establishing leadership in oncology, advancing pipeline development, and improving profitability. We believe the Company is set to emerge as the top oncology drugmaker by revenue this decade, thanks to both Seagen’s products and its own pipeline. During the Oncology Innovation Day in February 2024, Pfizer’s executives outlined their goal of introducing at least eight blockbuster cancer drugs by 2030 and expanding the proportion of biologics in their global revenue to 65%, from a previous 20% in 2023. This move is crucial as Merck (MRK), the current leader in oncology, is struggling to advance its next generation of cancer therapies. This also has the potential to support Pfizer’s valuations. Pfizer is making strides towards improved profitability, reflecting a key strategic aim with visible results. Adjusted gross margin increased by 3 percentage points to reach 79%, thanks to a decrease in the revenue contribution from COVID products and the introduction of a cost optimization program for manufacturing, targeting $1.5 billion in cost savings by 2027 and projected to enhance gross margins. The ongoing cost reprioritization initiative aims to control the increase in operating expenses relative to revenue, potentially supporting EPS growth through 2024 and 2025. PFE stock is trading at attractive valuations. Technical analysis implies a continued upside. PFE stock trades at P/E NTM of 10.4, which is below the Company’s pre-pandemic average of 12.5. We consider such a discount unfair, given the anticipated acceleration of Pfizer’s revenue and EPS growth over the next 2-3 years compared to the pre-covid dynamics. The technical indicators imply the stock passed a reversal “hammer” pattern on August 16. The price rebounded from the lower limit of the new ascending channel, confirming that its position is confidently set above the 200-day moving average. In our view, the PFE price is starting a medium-term upward movement, which is evidenced by fundamental undervaluation and several technical signals: the golden cross, resistance at the lower boundary of the ascending price channel, and reversal candlestick patterns. Based on this analysis, we assign a “Buy” rating to PFE stock with a target price of $32.90 over a two-month horizon. A stop-loss order is recommended to be set below the 200-day moving average at $26.90.
NSE:PFIZERLong
by FreedomHolding
Bullish Continuation Setup in Pfizer LtdThis daily chart of Pfizer Ltd. shows a bullish continuation pattern with Fibonacci extension levels highlighting potential upside targets. The Fibonacci retracement is drawn from the recent swing low at ₹5,754.70 to the swing high at ₹6,338.25, with the price currently above the key retracement zone, suggesting a possible resumption of the uptrend. The next significant targets based on the Fibonacci extensions are ₹6,698.95 (1.618 extension) and ₹7,282.50 (2.618 extension). These levels represent potential resistance zones where traders may consider taking profits. Key Levels: Support: ₹5,754.70 (Fibonacci 0.0 retracement) Resistance: ₹6,338.25 (Fibonacci 1.0 retracement) Potential Targets: ₹6,698.95 (1.618 Fibonacci extension), ₹7,282.50 (2.618 Fibonacci extension) Analysis: The price action is showing bullish momentum as it approaches the 1.618 Fibonacci extension level. A sustained move above ₹6,338.25 could lead to further gains, targeting the next extension levels. Traders should monitor volume and price action around these key resistance levels to gauge the strength of the move.
NSE:PFIZERLong
by Shivam_Bhanot
PFIZER: Consolidating at the resistanceThe chart is self-explanatory as always :) If you'd like to request an analysis, simply send us 100 coins as a token, and we'll be happy to post one for you. ⚠️Disclaimer: We are not registered advisors. The views expressed here are merely personal opinions. Irrespective of the language used, Nothing mentioned here should be considered as advice or recommendation. Please consult with your financial advisors before making any investment decisions. Like everybody else, we too can be wrong at times ✌🏻
NSE:PFIZER
by TheChartereds
Pfizer getting ready to make rapid movesPfizer is one of the world’s leading pharmaceutical company specializes in vaccines, hospitals, internal medicines and inflammation and immunology. Their manufacturing capacity is 4 billion tablets annually and supplied in neighboring countries of India. Pfizer CMP is 3866. Negative aspects of the company are high valuation (P.E. = 28.3), MFs are decreasing stake. Positive aspects of the company are increasing annual net profits, improving cash from operations annual, no debt, FIIs are increasing stake and zero promoter pledge. Entry can be taken after closing above 3901. Targets in the stock will be 3975 and 4006. Long term target in the stock will be 4069 and 4129. Stop loss in the stock should be maintained at closing below 3696.
NSE:PFIZERLong
by Happy_Candles_Investment